Agonists targeting co-stimulatory immune-checkpoint receptors such as CD40 and OX40 have shown potential in increasing antitumor immunity in HCC to convert tumors from cold to hot phenotypes. The gene discussed is CD40; the disease is hepatocellular carcinoma.